This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty.

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After ...

Former institutional trader Kevin Muir flags caution on chasing this market as he sees some big market whales nearing the end of a U.S. stock buying spree.

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to ...

Sarepta's stock has collapsed this year after two patients taking its Elevidys drug for Duchenne muscular dystrophy died of acute liver failure. Through Wednesday's close, its shares were down 85% ...